Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2020

View Archived Issues

CRISPR sheds LICHT on brain development

Macrophages metabolically support muscle

Seeing where tau goes wrong

Hoth outlines progress within COVID-19 pipeline

Sorrento Therapeutics synthesizes multispecific antigen-binding protein complexes

New anti-CD40 antibodies described by Nankai University

Memorial Sloan-Kettering Cancer Center presents CD19 antibodies

New wee1-like protein kinase inhibitors discovered at Nuvation Bio

Roche identifies new monoglyceride lipase inhibitors

Preliminary first-in-human data for [11C]MeDAS PET tracer

BlueWillow Biologics presents preclinical data on NanoVaz and S-2P-NE01

Discovery of novel DNA-PK inhibitors as radiosensitizers

[68Ga]Desferal developed for imaging of bacterial infections

Calithera expands phase I/II trial of telaglenastat with palbociclib to include pancreatic cancer

First results for KSQ-4279 in treatment of BRCA-deficient cancers

Microbiome confounders research complicates control groups

PK and safety data for nacubactam in combination with beta-lactams

Phase IIb/III study opens in U.S. with mesdopetam for troublesome dyskinesias in Parkinson's

[18F]FSU-880 imaging evaluated in prostate cancer patients with biochemical recurrence

Hangzhou Zhengxiang Pharmaceuticals patents PI3K-gamma inhibitors

Synlogic advances SYNB-8802 into phase I study for treatment of enteric hyperoxaluria

E.U. approval of Lynparza with bevacizumab for first-line maintenance in HRD-positive ovarian cancer

Chinese clearance for phase III trial of APL-1202 for first-line nonmuscle invasive bladder cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...